X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare WYETH LTD with ALEMBIC LTD - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

WYETH LTD vs ALEMBIC LTD - Comparison Results

WYETH LTD    Change

Wyeth Limited is the 51% subsidiary of Wyeth, US and is the sixth largest company among multinationals with revenues of Rs 2.9 bn in FY07. The company derives its revenues from pharmaceutical and OTC segments with focus on various therapeutic areas s... More

ALEMBIC LTD 
   Change

Alembic Limited, in its 99 years of existence, has evolved from being a tincture manufacturer to one of the prominent indigenous pharma companies in India. It is among the top players in the macrolides (anti-infective) and anti-microbials (animal hea... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    WYETH LTD ALEMBIC LTD WYETH LTD/
ALEMBIC LTD
 
P/E (TTM) x 27.7 58.4 47.5% View Chart
P/BV x 5.3 2.4 219.4% View Chart
Dividend Yield % 1.3 0.4 304.4%  

Financials

 WYETH LTD   ALEMBIC LTD
EQUITY SHARE DATA
    WYETH LTD
Mar-13
ALEMBIC LTD
Mar-18
WYETH LTD/
ALEMBIC LTD
5-Yr Chart
Click to enlarge
High Rs1,04472 1,450.6%   
Low Rs81834 2,413.0%   
Sales per share (Unadj.) Rs298.64.7 6,351.6%  
Earnings per share (Unadj.) Rs57.26.1 937.8%  
Cash flow per share (Unadj.) Rs58.46.2 935.3%  
Dividends per share (Unadj.) Rs17.000.20 8,500.0%  
Dividend yield (eoy) %1.80.4 483.3%  
Book value per share (Unadj.) Rs249.540.7 613.5%  
Shares outstanding (eoy) m22.72267.03 8.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.111.3 27.7%   
Avg P/E ratio x16.38.7 187.5%  
P/CF ratio (eoy) x15.98.5 188.0%  
Price / Book Value ratio x3.71.3 286.6%  
Dividend payout %29.73.3 906.4%   
Avg Mkt Cap Rs m21,15714,139 149.6%   
No. of employees `0000.5NA-   
Total wages/salary Rs m400207 192.9%   
Avg. sales/employee Rs Th13,787.4NM-  
Avg. wages/employee Rs Th813.0NM-  
Avg. net profit/employee Rs Th2,643.3NM-  
INCOME DATA
Net Sales Rs m6,7831,255 540.4%  
Other income Rs m353370 95.2%   
Total revenues Rs m7,1361,625 439.0%   
Gross profit Rs m1,617111 1,455.7%  
Depreciation Rs m2738 70.4%   
Interest Rs m62 323.5%   
Profit before tax Rs m1,938442 438.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m01,212 0.0%   
Extraordinary Inc (Exp) Rs m-50-   
Tax Rs m63224 2,639.7%   
Profit after tax Rs m1,3011,630 79.8%  
Gross profit margin %23.88.9 269.4%  
Effective tax rate %32.65.4 601.8%   
Net profit margin %19.2129.8 14.8%  
BALANCE SHEET DATA
Current assets Rs m6,9841,867 374.1%   
Current liabilities Rs m2,056591 347.8%   
Net working cap to sales %72.6101.6 71.5%  
Current ratio x3.43.2 107.6%  
Inventory Days Days9994 105.3%  
Debtors Days Days2474 32.6%  
Net fixed assets Rs m2441,791 13.6%   
Share capital Rs m227534 42.5%   
"Free" reserves Rs m5,44110,324 52.7%   
Net worth Rs m5,66810,858 52.2%   
Long term debt Rs m2541 60.7%   
Total assets Rs m7,90111,591 68.2%  
Interest coverage x353.3260.9 135.4%   
Debt to equity ratio x00 116.2%  
Sales to assets ratio x0.90.1 792.8%   
Return on assets %16.514.1 117.4%  
Return on equity %22.915.0 152.9%  
Return on capital %34.015.2 224.1%  
Exports to sales %0.21.5 14.1%   
Imports to sales %36.321.0 173.2%   
Exports (fob) Rs m1519 76.3%   
Imports (cif) Rs m2,465263 936.2%   
Fx inflow Rs m1519 78.4%   
Fx outflow Rs m2,677264 1,014.8%   
Net fx Rs m-2,662-244 1,089.1%   
CASH FLOW
From Operations Rs m923236 391.5%  
From Investments Rs m317-224 -141.5%  
From Financial Activity Rs m-481-27 1,808.3%  
Net Cashflow Rs m759-15 -5,129.1%  

Share Holding

Indian Promoters % 0.0 64.0 -  
Foreign collaborators % 51.1 0.0 -  
Indian inst/Mut Fund % 11.3 0.2 5,650.0%  
FIIs % 7.2 9.7 74.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 30.4 26.1 116.5%  
Shareholders   21,978 54,701 40.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare WYETH LTD With:   FDC LTD.  UNICHEM LAB  CIPLA  AJANTA PHARMA  FULFORD INDIA  

Compare WYETH LTD With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 170 Points Lower, Realty and FMCG Stocks Witness Selling(Closing)

After opening the day on a positive note, share markets in India witnessed volatile trading activity and ended in red.

Related Views on News

ALEMBIC LTD Announces Quarterly Results (1QFY19); Net Profit Up 106.9% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, ALEMBIC LTD has posted a net profit of Rs 69 m (up 106.9% YoY). Sales on the other hand came in at Rs 445 m (up 50.4% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

ALEMBIC LTD Announces Quarterly Results (4QFY18); Net Profit Up 64.9% (Quarterly Result Update)

Jul 20, 2018 | Updated on Jul 20, 2018

For the quarter ended March 2018, ALEMBIC LTD has posted a net profit of Rs 46 m (up 64.9% YoY). Sales on the other hand came in at Rs 332 m (up 0.9% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Is It the Right Time to Buy Pharma Stocks Now?(The 5 Minute Wrapup)

Sep 12, 2018

Is the pharma sector poised for a comeback? Is the worst over? I believe so.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

The Secret Of Mirae Asset India Equity Fund's Increasing Popularity(Outside View)

Sep 7, 2018

The prudent investment strategies followed at the fund house has helped Mirae Asset India Equity Fund earn a tag of being a consistent performer, which is in turn gaining popularity among investors.

Should You Be Worried About the Rising Dollar?(Chart Of The Day)

Sep 7, 2018

While the rupee has deprecated by about 5% annually since 1990 against the dollar, the BSE Sensex has returned 14% annually in the same period.

Revenge of the Ratings Agencies(Vivek Kaul's Diary)

Sep 7, 2018

Do you remember when ratings agencies ruled financial markets? Nick explains why he thinks it's time to prepare yourselves for a comeback of the ratings agencies.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

WYETH LTD SHARE PRICE


Dec 9, 2014 (Close)

TRACK WYETH LTD

  • Track your investment in WYETH LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

WYETH LTD - JUBILANT LIFE SCIENCES COMPARISON

COMPARE WYETH LTD WITH

MARKET STATS